Form 4: Myriad Genetics COO Awarded Performance-Based Restricted Stock Units

Mark Verratti, Chief Operating Officer of Myriad Genetics, was granted performance-based restricted stock units (PSUs) on April 30, 2025, tied to the company's stock price performance.

Summary

• Mark Verratti, the Chief Operating Officer of Myriad Genetics, received an award of performance-based restricted stock units (PSUs) on April 30, 2025.
• The PSUs are contingent upon Myriad Genetics achieving specific stock price milestones.
• A maximum of 105,785 shares of common stock may vest if all milestones are met.
• The Compensation and Human Capital Committee must certify the achievement of each milestone for the PSUs to vest.
• 25% of the shares will vest upon the achievement of each of the four stock price milestones.
• Vesting is also subject to Verratti's continued employment or service through the applicable vesting date.
• No portion of the PSUs may vest earlier than April 30, 2026.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of PSUs is a standard practice, and the performance-based nature aligns executive interests with shareholder value. However, the actual value depends on future performance.

Positives

• The performance-based nature of the stock units aligns executive compensation with shareholder value.
• The long-term vesting schedule encourages continued service and commitment from the COO.
• Achievement of stock price milestones could indicate strong company performance and growth.

Risks

• The stock price milestones may not be achieved, resulting in no or partial vesting of the PSUs.
• Mark Verratti's employment may terminate before the vesting dates, resulting in forfeiture of the PSUs.
• The value of the shares may fluctuate, impacting the actual value of the vested PSUs.

Future Outlook

The vesting of the PSUs is dependent on the future stock price performance of Myriad Genetics and the continued employment of Mark Verratti.

Industry Context

Granting performance-based equity compensation is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. The specific stock price milestones would need to be analyzed in the context of Myriad Genetics' strategic goals and industry benchmarks.

Comparison to Industry Standards

• Many biotechnology companies use performance-based equity awards to incentivize their executives.
• The specific terms of the PSUs, such as the stock price milestones and vesting schedule, would need to be compared to those of similar companies to assess their competitiveness.
• Companies like Exact Sciences and Illumina also use a mix of stock options and restricted stock units to compensate their executives, often tied to revenue growth, product development milestones, and stock price appreciation.

Stakeholder Impact

• Shareholders: The performance-based compensation structure aims to align executive incentives with shareholder value creation.
• Employees: The grant could motivate employees by aligning the COO's interests with the company's success.
• Management: The grant incentivizes the COO to drive company performance and achieve stock price milestones.

Key Dates

Keywords

performance-based restricted stock units, PSUs, stock price milestones, executive compensation, Myriad Genetics, Mark Verratti, COO, vesting